Postgraduate Medical Institute. Focused on Excellence

UCL Partners gets green light from NHS England

James Hampton-Till

James Hampton-Till

UCLPartners, the academic health partnership that includes Anglia Ruskin University, has been named as one of NHS England's new Academic Health Science Networks (AHSNs).

AHSNs have the potential to transform healthcare by putting innovation at the heart of the NHS, enabling academics, healthcare professionals and industry to work together to speed up delivery of cutting edge medical research into routine practice.

The result will be lives saved and a boost to the UK economy as inventors and industry join forces to develop new medical technologies for the benefit of patients.
NHS England's Chief Executive, Sir David Nicholson, said:

"The NHS is full of brilliant people with brilliant ideas. To spread ideas right across the NHS means working collaboratively with all those who have an interest.

AHSNs offer a more systematic delivery mechanism so that innovation spreads quickly and successfully through the NHS, making the best possible use of precious NHS resources and in ensuring the most advanced treatments, technologies and medicines are available to patients."

UCLPartners is the only AHSN that is already delivering quality improvements to healthcare at scale. It is also one of the largest in the country serving a diverse population - over six million people in north east and north central London, south and west Hertfordshire, south Bedfordshire and south west and mid Essex.
Professor James Hampton-Till, Director of Research at Anglia Ruskin University's Postgraduate Medical Institute, said:

"This is excellent news for Anglia Ruskin University. Being part of UCLPartners' Academic Health Science Network means thinking as a system, not as an individual university.

We can work more closely with our clinical and academic partners, drawing on the highly skilled and committed staff across our organisations. It's a fantastic opportunity to give our populations the healthcare they deserve."

Led by Professor Hampton-Till, UCLPartners is driving the delivery of a complex international phase III drug trial for patients with acute heart failure in parts of London, Essex and Hertfordshire. This is a priority study for Novartis, which will run across eight acute hospitals.
Professor Hampton-Till said:

"Our partnership draws together specialist expertise with detailed local knowledge and, by keeping the patient experience at the heart of what we do, can deliver high performing and scientifically important clinical trials."

UCLPartners is now building on its achievement to roll out programmes in areas that account for over 80% of premature mortality and current healthcare spend including cancer, cardiovascular and mental health.

For further information about UCLPartners, visit www.uclpartners.com.
Bookmark this page with: